Efficacy and Tolerability of SPN-804, a Novel, Once-Daily, Extended-Release Formulation of Oxcarbazepine: Adjunctive Treatment of Refractory Partial Seizures in a North American Subpopulation

被引：0
|
作者：
Johnson, Janet [1 ]
Brittain, Scott [1 ]
Louro, Dawn [1 ]
机构：
[1] Supernus Pharmaceut Inc, Rockville, MD USA
来源：
NEUROLOGY | 2013年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P02213
引用
收藏
页数：1
相关论文
共 40 条
  • [31] A DOUBLE-BLIND COMPARISON OF THE EFFICACY AND SAFETY OF KETOPROFEN EXTENDED-RELEASE (200 MG ONCE-DAILY) AND DICLOFENAC (75 MG TWICE-DAILY) FOR TREATMENT OF OSTEOARTHRITIS
    KENNEDY, AC
    MULLEN, BJ
    ROTH, SH
    GERMAIN, BF
    BONEBRAKE, RA
    WEI, N
    WILLKENS, RF
    LAWSON, JG
    APPELROUTH, DJ
    WHITE, RE
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1994, 55 (02): : 119 - 132
  • [32] Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation
    Beckebaum, Susanne
    Iacob, Speranta
    Sweid, Dani
    Sotiropoulos, Georgios C.
    Saner, Fuat
    Kaiser, Gernot
    Radtke, Arnold
    Klein, Christian G.
    Erim, Yesim
    de Geest, Sabina
    Paul, Andreas
    Gerken, Guido
    Cicinnati, Vito R.
    TRANSPLANT INTERNATIONAL, 2011, 24 (07) : 666 - 675
  • [33] CONVERSION FROM A TWICE-DAILY TACROLIMUS-BASED REGIMEN TO ONCE-DAILY TACROLIMUS EXTENDED-RELEASE FORMULATION IN STABLE PEDIATRIC LIVER TRANSPLANT RECIPIENTS: EFFICACY, SAFETY, AND IMMUNOSUPPRESSANT ADHERENCE
    Quintero, Jesus
    Juamperez, Javier
    Sanchez, Marta
    Misercahs, Mar
    Bilbao, Itxarone
    Charco, Ramon
    TRANSPLANT INTERNATIONAL, 2015, 28 : 200 - 200
  • [34] Safety and Tolerability of a Once-Daily, Extended-Release Memantine Formulation (28 mg) in Patients with Moderate to Severe Alzheimer's Disease: Results of a 52-Week Open-Label Trial
    Meyers, Barnett S.
    Lin, Min
    Graham, Stephen M.
    NEUROLOGY, 2010, 74 (09) : A269 - A269
  • [35] Safety and Tolerability of a Once-Daily, Extended-Release Memantine Formulation (28 Mg) in Patients with Moderate to Severe Alzheimer's Disease: Results of a 52-Week Open-Label Trial
    Meyers, Barnett S.
    Lin, Min
    Graham, Stephen M.
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2010, 18 (03): : S72 - S72
  • [36] A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children
    Nasser, Azmi
    Liranso, Tesfaye
    Adewole, Toyin
    Fry, Nicholas
    Hull, Joseph T.
    Chowdhry, Fatima
    Busse, Gregory D.
    Cutler, Andrew J.
    Jones, Nandita Joshi
    Findling, Robert L.
    Schwabe, Stefan
    CLINICAL THERAPEUTICS, 2020, 42 (08) : 1452 - 1466
  • [37] Clinical and bacteriological outcomes in a comparative study of the efficacy and tolerability of once-daily clarithromycin extended-release (CLA-ER) vs. twice-daily amoxicillin/clavulanate (A/C) for the treatment of subjects with acute maxillary sinusitis (ANIS)
    Riffer, E
    Palmer, R
    Spiller, J
    Busman, T
    Valdes, J
    Olson, C
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 : S166 - S166
  • [38] EFFICACY AND SAFETY OF ONCE-DAILY ADJUNCTIVE PERAMPANEL, A SELECTIVE AMPA ANTAGONIST: A POOLED ANALYSIS OF THREE PHASE III TRIALS IN PATIENTS WITH TREATMENT-RESISTANT PARTIAL-ONSET SEIZURES
    Ben-Menachem, E.
    Krauss, G. L.
    Noachtar, S.
    Serratosa, J. M.
    Squillacote, D.
    Yang, H.
    Zhu, J.
    Laurenza, A.
    EPILEPSIA, 2012, 53 : 190 - 191
  • [39] Efficacy and tolerability of once-daily OROS® hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain:: Results of a 6-week, randomized, open-label, noninferiority analysis
    Hale, Martin
    Tudor, Lulia Cristina
    Khanna, Sarita
    Thipphawong, John
    CLINICAL THERAPEUTICS, 2007, 29 (05) : 874 - 888
  • [40] Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage® XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise:: results from two double-blind, placebo-controlled studies
    Fujioka, K
    Brazg, RL
    Raz, I
    Bruce, S
    Joyal, S
    Swanink, R
    Pans, M
    DIABETES OBESITY & METABOLISM, 2005, 7 (01): : 28 - 39
1234